Under the terms of the proposed agreement, Neuphoria Therapeutics (NASDAQ: NEUP) stockholders are slated to retain an 11.1% stake in the newly combined entity. Attorney Juan Monteverde, whose firm is recognized in the 2025 ISS Securities Class Action Services Report, is currently reviewing the financial merits of the arrangement to ensure shareholder interests are protected.
In section Releases
Monteverde & Associates Launches Investigation into Neuphoria Merger
A potential conflict looms for Neuphoria Therapeutics shareholders following the announcement of a merger with Scancell Holdings plc. As the deal progresses, New York-based law firm Monteverde & Associates PC has opened an investigation to determine whether the transaction offers fair value to the company's investors.
Investors holding common stock in Neuphoria Therapeutics who have concerns regarding the merger's impact on their equity can contact the firm for a review. Monteverde & Associates, based out of the Empire State Building, specializes in securities litigation and has previously secured multi-million dollar recoveries for clients. Interested parties may reach out to Juan Monteverde at 212-971-1341 or via email to discuss the specifics of the investigation at no cost.
Comments (0)
No comments yet. Be the first!